AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…
17articles mentioning drugs
41drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: nab-paclitaxel ×
nab-paclitaxel
This drug is selected. Its supporting articles are shown below.
Articles mentioning nab-paclitaxel
17 articles · page 2 of 2HCB101HCB101-basedHCB101-201nab-paclitaxelramucirumabpaclitaxeltoripalimabgastric cancerhead and neck squamous cell carcinomatriple-negative breast cancer+1 more
… plus ramucirumab and paclitaxel); and b) first-line (1L) TNBC (HCB101 plus toripalimab and nab-paclitaxel). Primary endpoints were sa…
ipilimumabNivolumabsunitinibnab-paclitaxelAtezolizumabCTLA-4UT Southwestern Medical CenterN Engl J Med
…23–34.Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cel…
Cadonilimabcisplatinpaclitaxelnab-paclitaxeltaxaneESCCadvanced esophageal squamous cell carcinoma (ESCC)chemotherapy
…erse events were reported in 53.5% (23/43) patients.Conclusions Cadonilimab combined with taxane and cisplatin as first-line treatment reve…
gemcitabineGemcitabineABRaxaneIRInotecanOXaliplatine-2GEMBRAXnab-paclitaxelPancreatic adenocarcinomaFFXmPCFOLFIRINOXFrench National Agency for the Safety of Health Products
…revious phase Ib-II trial, we evaluated a sequential regimen of gemcitabine plus nab-paclitaxel (GEMBRAX) followed by FOLFIRINOX (FFX), whi…